Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immune-Path Biotechnology (Suzhou) Co. Ltd. has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to a distinct examiner, JADHAO, SAMADHAN JAISING, who is also the busiest examiner for the company with 1 pending action. This indicates a very focused prosecution effort where the immediate future of the company's US patent rights depends on a single examiner's review. The applicant should prioritize understanding the specific scientific interpretations favored by this examiner.
The portfolio's presence in a distinct art unit suggests that the technology being patented is specialized and falls within a specific regulatory or technical category. Because there is a distinct examiner involved, the applicant can develop a highly personalized approach to the prosecution, focusing exclusively on the requirements of JADHAO, SAMADHAN JAISING. This avoids the complexity of managing different examiner styles or conflicting art unit policies. A successful resolution here could set a strong precedent for future filings in this technical area.
For a company in the Biotechnology & Pharmaceuticals sector, having a pending office action represents a narrow but critical point of engagement with the USPTO. The prosecution team can concentrate their efforts on the distinct art unit where the application is being reviewed. This singular focus allows for a deep dive into the specific prior art cited by the examiner currently overseeing the portfolio's active case. This targeted approach is often more efficient than managing a broad, multi-front prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JADHAO, SAMADHAN JAISING | 1 | 46.9% | +46.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17623862 | Recombinant Human Papillomavirus Vaccine Composition and Use thereof | JADHAO, SAMADHAN JAISING | 77d overdue |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17623862 | Recombinant Human Papillomavirus Vaccine Composition and Use thereof | JADHAO, SAMADHAN JAISING | 1672 | §103 | Final Rejection | 77d overdue | Pending | Dec 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial